Vemurafenib

Global STAT3 Inhibitors Market & Clinical Trials Outlook 2028: Featuring Novartis, Incyte, Tvardi & More - ResearchAndMarkets.com

Retrieved on: 
Friday, January 27, 2023
Health, Pharmaceutical, Novartis, PD-1, Drug tolerance, STAT3, Melanoma, Malignancy, Software, EMA, Research, Neoplasm, Therapy, Immune system, Vemurafenib, FDA, Growth, Cancer, Infection, Pharmaceutical industry, Vaccine

The "Global STAT3 Inhibitors Market & Clinical Trials Outlook 2028" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global STAT3 Inhibitors Market & Clinical Trials Outlook 2028" report has been added to ResearchAndMarkets.com's offering.
  • The dysregulation of STAT3 has been implicated in several malignancies which have brought it into the spotlight for cancer treatment.
  • With a few candidates in the phase II of clinical trials, we may expect some of them to get approval within the next decade.
  • The most popular combination which has been suggested and further evaluated in clinical trials is combining the STAT3 with inhibitors of immune checkpoints, especially PD-1.

Global STAT3 Inhibitors Market & Clinical Trials Outlook 2028: Insight and Analysis on Over 30 Drugs and 20 Companies

Retrieved on: 
Friday, January 27, 2023
Therapy, EMA, Software, Melanoma, Infection, Drug tolerance, Malignancy, PD-1, FDA, Cancer, Growth, STAT3, Novartis, Neoplasm, Vemurafenib, Research, Immune system, Pharmaceutical industry, Vaccine

DUBLIN, Jan. 27, 2023 /PRNewswire/ -- The "Global STAT3 Inhibitors Market & Clinical Trials Outlook 2028" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, Jan. 27, 2023 /PRNewswire/ -- The "Global STAT3 Inhibitors Market & Clinical Trials Outlook 2028" report has been added to ResearchAndMarkets.com's offering.
  • The dysregulation of STAT3 has been implicated in several malignancies which have brought it into the spotlight for cancer treatment.
  • With a few candidates in the phase II of clinical trials, we may expect some of them to get approval within the next decade.
  • The most popular combination which has been suggested and further evaluated in clinical trials is combining the STAT3 with inhibitors of immune checkpoints, especially PD-1.

Aquestive Therapeutics and Haisco Pharmaceutical Group Enter Licensing and Supply Agreement for Riluzole Oral Film for ALS Treatment in China

Retrieved on: 
Thursday, March 3, 2022
Purging disorder, Security (finance), Degenerative disease, Neutropenia, Urine, Enoxacin, U.S. Securities and Exchange Commission, Tongue, Hypertension, ALS, CYP1A2, News, FDA, Therapy, Drug development, Anaphylaxis, LinkedIn, Company, Development, Food, Caregiver, Jaundice, Water, Methoxsalen, Tablet, Vomiting, Fluvoxamine, Cough, Clobazam, Nausea, Fatigue, CNS, Fever, Mexiletine, Tiabendazole, Seizure, Riluzole, NASDAQ, Allergy, Lennox–Gastaut syndrome, Viscosity, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Patient, HIV disease progression rates, Liver, Central nervous system, Safety, Weakness, Abdominal pain, Vemurafenib, SZSE, Hepatotoxicity, Ciprofloxacin, GLOBE, Amyotrophic lateral sclerosis, Pharmaceutical industry

Around 85% of ALS patients suffer from a progressive loss of bulbar functionality.1 Swallowing food and liquids becomes more difficult over time.

Key Points: 
  • Around 85% of ALS patients suffer from a progressive loss of bulbar functionality.1 Swallowing food and liquids becomes more difficult over time.
  • This agreement with Haisco will allow ALS patients in China to access EXSERVAN, a riluzole oral film, which will provide a meaningful treatment option to those who have to discontinue their treatment because of difficulties swallowing a tablet.
  • Pursuant to the agreement, Haisco will lead the regulatory and commercialization activities for EXSERVAN in China.
  • EXSERVAN, an oral film formulation of riluzole, was developed by Aquestive using its PharmFilminnovative drug delivery technology.

Black Diamond Therapeutics Reports Third Quarter 2021 Financial Results and Provides Corporate Update

Retrieved on: 
Monday, November 8, 2021
Diamond, PK, FGFR, Lung cancer, Cancer, Private Securities Litigation Reform Act, Perk, Class, Clinical trial, R, Oncogene, Human, GBM, Vemurafenib, Investment, M26 Modular Accessory Shotgun System, Hyperphosphatemia, COVID-19, NEW, EGFR, Program, Annual report, Partnership, FGFR2, Conference, Company, Research, Black Diamond, Glioblastoma, Large-cell lung carcinoma, GLOBE, U.S. Securities and Exchange Commission, NSCLC, Drug discovery, BRAF, FGFR1, MAP, OpenEye Scientific Software, FGFR3, Nasdaq, Cell, Encorafenib, Patient, Dyckman Street station (IND Eighth Avenue Line), Pharmaceutical industry, Antibiotics, Trapping, Medical imaging, Lithium

and NEW YORK, Nov. 08, 2021 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and development of MasterKey therapies, today reported financial results for the third quarter ended September 30, 2021 and provided a corporate update.

Key Points: 
  • and NEW YORK, Nov. 08, 2021 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and development of MasterKey therapies, today reported financial results for the third quarter ended September 30, 2021 and provided a corporate update.
  • Black Diamond remains on-track with preparations for initiating the Phase 2 portion of the MasterKey-01 Phase 1/2 study of BDTX-189 by the end of 2021.
  • Black Diamond continues to advance BDTX-1535 through IND-enabling studies and expects to file an IND application by the first half of 2022.
  • Black Diamond continues to progress its early-stage pipeline programs designed to target cancers driven by mutations in BRAF and FGFR.

Black Diamond Therapeutics Presents Preclinical Data on BDTX-1535, BRAF, and FGFR Programs at the 33rd AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Retrieved on: 
Friday, October 8, 2021
Diamond, Private Securities Litigation Reform Act, Company, Brain, Neoplasm, Large-cell lung carcinoma, MAP, EGFR, Conference, Drug discovery, BRAF, M26 Modular Accessory Shotgun System, COVID-19, NEW, Black Diamond, Cell, Program, GBM, GLOBE, FGFR2, Investigational New Drug, Cancer, Precision medicine, Annual report, Glioblastoma, Class, Mutation, FGFR1, U.S. Securities and Exchange Commission, Hyperphosphatemia, Vemurafenib, Human, Toxic shock syndrome toxin, Dyckman Street station (IND Eighth Avenue Line), AACR, FGFR3, FGFR, Perk, Encorafenib, Oncogene, Patient, Secondary malignant neoplasm, Nasdaq, Pharmaceutical industry, Medical imaging, Antibiotics, Vaccine, Trapping, Abrasive

Black Diamond expects to file an Investigational New Drug (IND) application for BDTX-1535 in the first half of 2022.

Key Points: 
  • Black Diamond expects to file an Investigational New Drug (IND) application for BDTX-1535 in the first half of 2022.
  • The presentations from the AACR-NCI-EORTC meeting are available on the Scientific Presentations and Publications section of the Black Diamond Therapeutics website.
  • Black Diamond is built upon a deep understanding of cancer genetics, protein structure and function, and medicinal chemistry.
  • Black Diamond was founded by David M. Epstein, Ph.D., and Elizabeth Buck, Ph.D. For more information, please visit www.blackdiamondtherapeutics.com .

VectivBio Strengthens Business Development Capabilities with Key Appointments

Retrieved on: 
Wednesday, November 4, 2020
Daiichi Sankyo, Companies, Health care, Clinical medicine, Plexxikon, Vemurafenib, Pharmaceutical industry in China, PTC Therapeutics, Lonza Group

BASEL, Switzerland, Nov. 4, 2020 /PRNewswire/ -- VectivBio AG , a clinical-stage biotechnology company developing transformational medicines for patients with serious rare diseases, today announced the appointments of Sarah Holland, Ph.D. , as Chief Business Officer and Aditya Venugopal, Ph.D. , as Vice President of Business Development.

Key Points: 
  • BASEL, Switzerland, Nov. 4, 2020 /PRNewswire/ -- VectivBio AG , a clinical-stage biotechnology company developing transformational medicines for patients with serious rare diseases, today announced the appointments of Sarah Holland, Ph.D. , as Chief Business Officer and Aditya Venugopal, Ph.D. , as Vice President of Business Development.
  • Most recently, she served as Global Head of licensing at Lonza AG where she built the new licensing business unit, led research and development and drove the spin-off of Affinia Therapeutics.
  • She led many deals for Roche Partnering, including licensing ZELBORAF (vemurafenib) from Plexxikon and establishing a key CNS partnership with PTC Therapeutics.
  • Dr. Venugopal was most recently an Executive Director at Intercept Pharmaceuticals, where he held roles leading corporate strategic planning and business development (BD).

OnKure and Pfizer Enter Clinical Trial Collaboration and Supply Agreement to Evaluate Combination of OKI-179 and Binimetinib

Retrieved on: 
Monday, September 21, 2020
General Health, Health, Pharmaceutical, Clinical trials, Oncology, Clinical medicine, Medicine, Cancer, Oncogenes, Melanoma, RTT, Ras GTPase, BRAF, Targeted therapy, Binimetinib, Vemurafenib

Activating NRAS mutations occur in approximately 20% of melanomas, representing the second most common oncogenic driver mutation in melanoma after BRAF mutations.

Key Points: 
  • Activating NRAS mutations occur in approximately 20% of melanomas, representing the second most common oncogenic driver mutation in melanoma after BRAF mutations.
  • An unmet medical need remains for targeted therapy in metastatic patients harboring an NRAS mutation.
  • reported in Cancer Discovery, as well as preclinical combination studies conducted by OnKure, the rational combination of these two agents may enhance clinical benefit of MAPK inhibition in NRAS melanomas.
  • OnKure and Pfizer will form a Joint Development Committee to review clinical trial results from the OnKure-sponsored study.

Melanoma Research Alliance Hails FDA’s First ‘Triplet’ Combination Approval for Melanoma

Retrieved on: 
Monday, August 3, 2020
Research, Philanthropy, Health, Fund Raising, General Health, Other Philanthropy, Foundation, Other Science, Science, Cancer treatments, Clinical medicine, Medicine, Antineoplastic drugs, RTT, Cancer, Melanoma, Vemurafenib, Targeted therapy, Cobimetinib, Atezolizumab, BRAF

The newly approved triplet treatment is the first FDA-approved combination for metastatic melanoma that brings together immunotherapy with targeted therapies.

Key Points: 
  • The newly approved triplet treatment is the first FDA-approved combination for metastatic melanoma that brings together immunotherapy with targeted therapies.
  • In the study, the triplet combination of Tecentriq + Cotellic and Zelboraf was compared to placebo + Cotellic and Zelboraf among patients with advanced BRAF-mutant melanoma.
  • This approval demonstrates the innovative spirit within the melanoma research community, says Dr. Marc Hurlbert, MRA Chief Science Officer.
  • Due to the ongoing support of its founders, 100 percent of donations to MRA go directly to its melanoma research program.

FDA Approves First Therapy for Patients with Lung and Thyroid Cancers with a Certain Genetic Mutation or Fusion

Retrieved on: 
Friday, May 8, 2020
Health, Medicine, Chemical compounds, Cancer treatments, Chloroarenes, Clinical research, Clinical trial, Design of experiments, Pharmaceutical industry, Food and Drug Administration, Treatment of lung cancer, Vemurafenib

Retevmo is the first therapy approved specifically for cancer patients with the RET gene alterations.

Key Points: 
  • Retevmo is the first therapy approved specifically for cancer patients with the RET gene alterations.
  • "The FDA is committed to reviewing treatments like Retevmo that are targeted to specific subsets of patients with cancer."
  • The FDA approved Retevmo on the results of a clinical trial involving patients with each of the three types of tumors.
  • During the clinical trial, patients received 160 mg Retevmo orally twice daily until disease progression or unacceptable toxicity.

QIAGEN Launches Therascreen BRAF Test as Companion Diagnostic to a BRAFTOVI® (encorafenib) Based Regimen in Metastatic Colorectal Cancer

Retrieved on: 
Wednesday, April 15, 2020
Research, Medical Supplies, FDA, Biotechnology, Health, General Health, Other Science, Science, Oncology, Cancer, Clinical medicine, Medicine, Tyrosine kinase inhibitors, Cancer treatments, Mutation, V600E, RTT, BRAF, Colorectal cancer, MEK inhibitor, Vemurafenib

Colorectal cancer is the third most common type of cancer, and approximately 150,000 patients a year in the United States are diagnosed with CRC.

Key Points: 
  • Colorectal cancer is the third most common type of cancer, and approximately 150,000 patients a year in the United States are diagnosed with CRC.
  • The therascreen BRAF V600E kit runs on QIAGENs Rotor-Gene Q MDx, a member of the modular QIAsymphony family of automation solutions.
  • We are very excited about the launch of the new therascreen BRAF V600E Kit, our first companion diagnostic test to obtain FDA approval for the detection of a mutation in the BRAF gene and our third CDx approval in colorectal cancer.
  • The new therascreen BRAF V600E Kit will be available to accelerate the availability of innovations in precision medicine.